Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Neurology, Wuming Hospital of Guangxi Medical University, Nanning, China.
Brain Behav. 2022 Mar;12(3):e2524. doi: 10.1002/brb3.2524. Epub 2022 Feb 13.
Some acute ischemic stroke (AIS) patients still suffer from early neurological deterioration (END) after receiving intravenous thrombolysis (IVT), and these patients often have a poor prognosis. The purpose of our study is to observe the efficacy and safety of human urinary kallidinogenase (HUK) treatment in patients with END.
This was a retrospective analysis and 49 patients with END who met the inclusion criteria were divided into the observation group and the control group. All patients received routine treatment of AIS, while patients in the observation group were treated with HUK within 24 h after IVT and the other group without HUK.
There were 24 patients in the observation group and 25 patients in the control group. After treatment, favorable prognosis (mRS scores ≤2) at 3 months in the observation group with 13 cases (54.17%) was significantly better than that in the control group with four cases (16%) (p = .001), and there was no statistical difference between the two groups in any hemorrhagic complication.
HUK is considered to be safe and may improve the prognosis of AIS patients with END after IVT. More clinical trials are needed to validate these results in the future.
一些急性缺血性脑卒中（AIS）患者在接受静脉溶栓（IVT）后仍会发生早期神经功能恶化（END），这些患者的预后往往较差。本研究旨在观察人尿激肽原酶（HUK）治疗 END 患者的疗效和安全性。
这是一项回顾性分析，纳入符合标准的 49 例 END 患者，分为观察组和对照组。所有患者均接受 AIS 的常规治疗，观察组患者在 IVT 后 24 h 内使用 HUK 治疗，对照组患者未使用 HUK。
观察组 24 例，对照组 25 例。治疗后 3 个月观察组预后良好（mRS 评分≤2）13 例（54.17%）明显优于对照组 4 例（16%）（p=0.001），两组出血性并发症无统计学差异。
HUK 被认为是安全的，可能改善 IVT 后 END 的 AIS 患者的预后。未来需要更多的临床试验来验证这些结果。
